employee
employee
Russian Federation
GRNTI 76.33 Гигиена и эпидемиология
GRNTI 76.03 Медико-биологические дисциплины
OKSO 31.06.2001 Клиническая медицина
OKSO 31.08.08 Радиология
OKSO 32.08.12 Эпидемиология
OKSO 14.04.02 Ядерные физика и технологии
BBK 534 Общая диагностика
BBK 51 Социальная гигиена и организация здравоохранения. Гигиена. Эпидемиология
TBK 5712 Медицинская биология. Гистология
TBK 5734 Медицинская радиология и рентгенология
TBK 6212 Радиоактивные элементы и изотопы. Радиохимия
TBK 5708 Гигиена и санитария. Эпидемиология. Медицинская экология
The article reviews domestic and foreign literature on the use of radiation therapy in the treatment of medullary thyroid cancer. The possibilities of various radiation methods in the treatment of patients with distant metastases are shown. In addition to classical types of remote irradiation, data are presented on the possibilities of radionuclide therapy (peptide-receptor therapy with somatostatin analogs and radionuclide therapy with osteotropic drugs for bone metastases). Methods of combined therapy with the use of osteomodifying agents, targeted drugs and other methods are described, which make it possible to increase the effectiveness of treatment of patients with medullary thyroid cancer with bone metastases.
medullary cancer, bone metastases, external beam therapy, radionuclide therapy
1. Kaprin A.D., Starinskiy V.V., Petrova G.V. i dr. Sostoyanie onkologicheskoy pomoschi naseleniyu Rossii. Moskva. 2017.[Kaprin AD, Starinsky VV, Petrova GV. State of oncological care for the population of Russia. Moscow. 2017 (In Russian).]
2. Asimakopoulos P, Nixon IJ, Shaha AR. Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes. Clin Oncol (R Coll Radiol). 2017 May;29(5):283-89. DOI:https://doi.org/10.1016/j.clon.2017.01.001. Epub 2017 Jan 13. Review. PubMed PMID: 28094086; PubMed Central PMCID: PMC5541897.
3. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006 Nov 1;107(9):2134-42. PubMed PMID: 17019736.
4. Rumyancev PO, Rumyanceva UV. Targetnaya terapiya vandetanibom medullyarnogo raka schitovidnoy zhelezy u detey i podrostkov. Onkopediatriya, 2015;(2):115-120.[Rumyantsev PO, Rumyantseva UV. Targeted Therapy with Vandetanib Medullary Thyroid Carcinoma in Children and Adolescents. Oncopediatrics. 2015;2(2):115-20. DOI:https://doi.org/10.15690/onco. v2i2.1342]
5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73. PubMed PMID: 9578814.
6. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34. Epub 2005 Jan 5. PubMed PMID: 15634717.
7. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000 Mar 1;88(5):1139-48. PubMed PMID: 10699905.
8. Gómez K, Varghese J, Jiménez C. Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res. 2011;2011:815826. DOI:https://doi.org/10.4061/2011/815826. Epub 2011 May 16. PubMed PMID: 21687607; PubMed Central PMCID: PMC3112527.
9. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001 Jun; 8(2):135-47. Review. PubMed PMID: 11397669.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. PubMed PMID: 10655437.
11. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71. Review. PubMed PMID: 11739416.
12. Franc B, Rosenberg-Bourgin M, Caillou B, Dutrieux-Berger N, Floquet J, Houcke-Lecomte M, et ol. Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis). Hum Pathol. 1998 Oct;29(10):1078-84. PubMed PMID: 9781645.
13. Tuttle RM, Ball DW, Byrd D, et al. Medullary thyroid carcinoma. In Werner and Ingbar´s (Eds Braverman LE and Utiger RE) Philadelphia: Lippincott Williams & Wilkins. The Thyroid. Edn 8. P. 930-943
14. Kwon H, Kim WG, Sung TY, Jeon MJ, Song DE, Lee YM, et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma. J Surg Oncol. 2016 Feb;113(2):152-8. DOI:https://doi.org/10.1002/jso.24126. Epub 2015 Dec 14. PubMed PMID: 26799259.
15. Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW; European Thyroid Association Task Force. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012 Apr;1(1):5-14. DOI:https://doi.org/10.1159/000336977. Epub 2012 Mar 28. Erratum in: Eur Thyroid J. 2012;1(2):54.PubMed PMID: 24782992; PubMed Central PMCID: PMC3821456.
16. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun;19(6):565-612. DOI:https://doi.org/10.1089/thy.2008.0403. Review. Erratum in: Thyroid. 2009 Nov;19(11):1295. PubMed PMID: 19469690.
17. Ryzhkov A.D., Shiryaev S.V., Odzharova A.A., i dr. Osteoscintigrafiya metastazov v kosti s fosfatnymi soedineniyami, mechennymi 99mTc Medicinskaya radiologiya i radiacionnaya bezopasnost'. 2007;52(4):62-8. [Ryzhkov AD, Shiryaev SV, Odzharova AA, et al. Osteoscintigraphy of bone metastases with phosphate compounds labeled with 99mTc. J Medical Radiology and Radiation Safety. 2007;52.(4):62-8 (In Russian).]
18. Krylov V.V., Drozdovskiy B.Ya., Cyb A.F. Radionuklidnaya terapiya v palliativnom lechenii bol'nyh s metastazami v kosti Palliativnaya medicina i reabilitaciya. 2005;4:45-53. [Krylov VV, Drozdovsky BY, Tsyb AF. Radionuclide therapy in the palliative treatment of patients with bone metastases. J Palliative medicine and rehabilitation. 2005;4:45-53(In Russian).]
19. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. Review. PubMed PMID: 18084343.
20. Vorob'eva S.L. Radionuklidnye metody issledovaniya v diagnostike metastazov raka schitovidnoy zhelezy v kosti. Obninsk. Avtoref. diss. kand. med. nauk. 2006. [Vorobyova SL. Methods of radionuclide studies in the diagnosis of thyroid cancer metastases in the bone. Obninsk. Abstract of the dissertation of the candidate of medical sciences. 2006 (In Russian).]
21. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15(12):784-95. PubMed PMID: 2483138.
22. Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):475-85. DOIhttps://doi.org/10.1016/j.clon.2010.05.002. Review. PubMed PMID: 20627492.
23. Belozerova M.S., Kochetova T.Yu., Krylov V.V. Prakticheskie rekomendacii po radionuklidnoy terapii pri metastazah v kosti. Zlokachestvennye opuholi. 2016;4:506-12.[Belozerova MS, Kochetova TY, Krylov VV. Practical recommendations for radionuclide therapy for bone metastases. J Malignant tumors. 2016;4:506-12 (In Russian).]
24. Silberstein EB, Buscombe JR, McEwans A. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Society of nuclear medicine procedure guidelines manual. 2003:145-53.
25. Krylov V.V., Kochetova T.Yu., Belozerova M.S., Voloznev L.V. Osobennosti primeneniya razlichnyh radiofarmpreparatov v lechenii bol'nyh s metastazami v kosti. Palliativnaya medicina i reabilitaciya. 2015;(4):26-33.[Krylov VV, Kochetova TY, Belozerova MS, Voloznev LV. Features of the use of various radiopharmaceuticals in the treatment of patients with bone metastases. J Palliative medicine and rehabilitation. 2015;4:26-33 (In Russian).]
26. Kochetova T.Yu., Krylov V.V., Smolyarchuk M.Ya., Voloznev L.V., Lunev A.S. 188Re-zoledronovaya kislota - novyy otechestvennyy terapevticheskiy radiofarmacevticheskiy preparat: pervyy klinicheskiy opyt. Povolzhskiy onkologicheskiy vestnik. 2014;(3):41-7.[Kochetova TY, Krylov VV, Smolyarchuk MY., Voloznev LV, Lunev AS. 188Re-zoledronic acid is a new Russian adiodopharmaceutical to treat bone metastases: the first clinical experience. Volga Oncological Bulletin. 2014;3:41-7 (In Russian).]
27. Modnikov O.P., Novikov G.A., Rodionov V.V. Sovremennye podhody k lecheniyu mnozhestvennogo metastaticheskogo porazheniya kostey. V sb.: Kurs lekciy po palliativnoy pomoschi onkologicheskim bol'nym. 2004;1: 493-541[Modnikov OP, Novikov GA, Rodionov VV. Modern approaches to the treatment of multiple metastatic bone lesions. The course of lectures on palliative care for cancer patients edited by Novikov GA, Chissov VI, Modnikov OP. Moscow. 2004. Volume 1: 493-541 (In Russian).]
28. Krylov V.V. Radionuklidnaya terapiya samariem oksabiforom, 153Sm pri metastaticheskih porazheniyah kostey. Obninsk. Avtoref. diss. dokt. med. nauk. 2007. [Krylov VV. Radionuclide therapy with samarium oxabiphor, 153Sm for metastatic bone lesions. Obninsk. Abstract of the dissertation of a doctor of medical sciences. 2007(In Russian).]
29. Ryzhkov A.D., Gabuniya R.I., Kochergina N.V., Shiryaev S.V., Zimina O.G. Diagnostika i terapiya kostnyh metastazov s ispol'zovaniem Stronciya-89 Voprosy onkologii. 2004;50(6)658-62.[Ryzhkov AD, Gabuniya RI, Kochergina NV, Shiryaev SV, Zimina OG. Diagnosis and therapy of bone metastases using Strontium-89. J Questions of Oncology. 2004;50(6): 658-62 (In Russian).]
30. Krylov V.V., Kochetova T.Yu. Radionuklidnaya terapiya 188Re-gidroksietilidendifosfonatom v lechenii bol'nyh s metastazami v kosti. Medicinskaya radiologiya i radiacionnaya bezopasnost'. 2014;59(6)54-62. [Krylov VV, Kochetova TY. Radionuclide therapy with 188Re-hydroxyethylidene diphosphonate in the treatment of patients with bone metastases. J Medical Radiology and Radiation Safety. 2014;59(6):54-62 (In Russian).]
31. Kodina G.E., Gromova N.P., Tronova I.N., Inkin A.A., Drozdovskiy B.Ya., Krylov V.V. Radiofarmacevticheskaya kompoziciya. Patent na izobretenie RUS 2162714 20.06.2000.[Kodina GE, Gromova NP, Tronova IN, Inkin AA, Drozdovsky BY, Krylov VV. Radiopharmaceutical composition. Patent for invention RUS 2162714 06/20/2000.]
32. Turner J.H. Treatment of painful skeletal metastases. Alasbimn Journal. 2002. Special Issue: 8-th World Congress of Nuclear Medicine. N 17.
33. Krylov V.V., Karyakin O.B., Drozdovskiy B.Ya. Radionuklidnaya terapiya v lechenii bol'nyh rakom predstatel'noy zhelezy s metastazami v kosti. Onkourologiya. 2006;1:61-68. [Krylov VV, Karyakin OB, Drozdovsky BY. Radionuclide therapy in the treatment of patients with prostate cancer with bone metastases. J Oncourology. 2006;1:61-68.]
34. Krylov V.V., Drozdovskiy B.Ya., Timohina O.V., Garbuzov P.I., Rodichev A.A., Vorob'eva S.L. Radionuklidnaya terapiya 153Sm-oksabiforom v palliativnom lechenii bol'nyh rakom schitovidnoy zhelezy s metastazami v kostyah. Rossiyskiy onkologicheskiy zhurnal. 2007;5:16-21. [Krylov VV, Drozdovsky BY, Timokhina OV, et al. Radionuclide therapy with 153Sm-oxabiphor in palliative treatment of patients with thyroid cancer with bone metastases. Russian Oncological Journal. 2007;5:16-21(In Russian).]
35. Belozerova M.S., Kochetova T.Yu., Krylov V.V. Prakticheskie rekomendacii po radionuklidnoy terapii pri metastazah v kosti Zlokachestvennye opuholi. 2016;4:506-12. [Belozerova MS, Kochetova TY, Krylov VV. Practical recommendations for radionuclide therapy for bone metastases. Malignant tumors. 2016;4:506-12 (In Russian).]
36. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994 Mar 3;330(9):592-6. PubMed PMID: 7508092.
37. Enrique O, Zhongyun P, Parma EP. Efficacy and toxicity of Sm-153-EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med. 2002; 1(1) 21-27.
38. Belozerova M.S., Krylov V.V., Kochetova T.Yu., Shurinov A.Yu., Timohina O.V., Ikonnikov A.I., Poluektova M.V., Chirkova T.V., Vorob'eva O.A. Vozmozhnosti metoda prolongirovannoy radionuklidnoy terapii s ispol'zovaniem povtornyh vvedeniy samariya oksabifora 153Sm nizkoy razovoy aktivnosti u bol'nyh rakom molochnoy i predstatel'noy zhelez s metastazami v kosti. Radiaciya i organizm. Materialy nauchno-prakticheskoy konferencii. 2016:13-14. [Belozerova MS, Krylov VV, Kochetova TY, et al. The possibilities of the method of prolonged radionuclide therapy using repeated injections of samarium oxabifor 153Sm of low single activity in patients with breast and prostate cancer with bone metastases. In the book: Radiation and the body. Materials of the scientific-practical conference. 2016:13-4 (In Russian).]
39. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003 Aug 1;21(15):2869-75. PubMed PMID: 12885803.
40. Parker C, Nilsson S, Heinrich D, et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. DOI:https://doi.org/10.1056/NEJMoa1213755. PubMed PMID: 23863050.
41. Rasulova N.V., Lyubshin V.I., Arybzhanov D.T., Krylov V.V., Hodzhibekov M.H. Optimizaciya kombinirovannogo lecheniya bol'nyh s metastazami v kosti s ispol'zovaniem zomety i samariya-153 oksabifora. Medicinskaya nauka i obrazovanie Urala. 2012;13(2):57-9. [Rasulova NV, Lyubshin VI, Arybzhanov DT, et al. Optimization of the combined treatment of patients with bone metastases using zometa and samarium-153 oxabiphora. Medical Science and Education of the Urals. 2012;13(2):57-9.]
42. Rasulova N, Lyubshin V, Arybzhanov D, et al. of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): first experience. World J Nucl Med. 2013 Jan;12(1):19-23. DOI:https://doi.org/10.4103/1450-1147.113942. PubMed PMID: 23961251; PubMed Central PMCID: PMC3745628.
43. Rasulova N.V., Dzhalalov F.Z., Arybzhanov D.T., Hodzhibekov M.H., Krylov V.V. Pervyy opyt primeneniya novyh tehnologiy lecheniya kostnyh metastazov s patologicheskim perelomami pozvonkov i ugrozoy sdavleniya spinnogo mozga. Hirurgiya Uzbekistana. 2012;1:39-44.[Rasulova NV, Dzhalalov FZ, Arybzhanov DT, et al. The first experience of using new technologies for the treatment of bone metastases with pathological vertebral fractures and the threat of spinal cord compression. J Surgery of Uzbekistan. 2012;1: 39-44.]
44. Gulidov I.A., Krylov V.V., Luk'yanova E.V., Ryzhkov A.D., Nechushkin M.I., Ivanova I.N. Palliativnaya luchevaya terapiya kostnyh metastazov raka molochnoy zhelezy. Medicinskaya fizika. 2010;3:5-10.[Gulidov IA, Krylov VV, Lukyanova EV, et al. Palliative radiation therapy of bone metastases of breast cancer. J Medical Physics. 2010;3:5-10.]
45. Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015;204:207-25. DOI:https://doi.org/10.1007/978-3-319-22542-5_10. Review. PubMed PMID: 26494391.
46. Chatal JF, Campion L, Kraeber-Bodéré F, et al. French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006 Apr 10;24(11):1705-11. Epub 2006 Mar 20. PubMed PMID: 16549819.
47. Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007 Nov;92(11):4185-90. Epub 2007 Aug 28. PubMed PMID: 17726071.
